Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
Apr 8, 2025
12:25
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
